The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Margitta WormJacob P ThyssenSibylle SchliemannAndrea BauerVivian Y ShiBen EhstSandra TillmannSofie KornKatarina ResenTove AgnerPublished in: The British journal of dermatology (2022)
In this trial, delgocitinib cream showed a dose-response relationship in terms of efficacy and was well tolerated.